Nucleic acid aptamers as stabilizers of proteins: The stability of tetanus toxoid

Pharmaceutical Research

Volumn 30, Issue 7, 2013, Pages 1871-1882

  Jain, Nishant Kumar ^a   Jetani, Hardik C ^a   Roy, Ipsita ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

aptamers; controlled drug release; protein stability; tetanus toxoid; vaccine

Indexed keywords

APTAMER; MICROSPHERE; NUCLEIC ACID; POLYGLACTIN; TETANUS TOXOID;

ABSORPTION; ANTIGENICITY; ARTICLE; BINDING AFFINITY; COMBINATORIAL CHEMISTRY; DRUG STABILITY; ENCAPSULATION; IN VITRO STUDY; MOISTURE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN UNFOLDING; RNA SEQUENCE; SUSTAINED DRUG RELEASE; SYNTHESIS; WATER CONTENT; ZETA POTENTIAL;

APTAMERS, NUCLEOTIDE; BASE SEQUENCE; DELAYED-ACTION PREPARATIONS; LACTIC ACID; POLYGLYCOLIC ACID; PROTEIN STABILITY; PROTEIN UNFOLDING; TETANUS TOXOID;

EID: 84878834706     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1030-7     Document Type: Article

References (48)

1. Van der Zeijst BA. Vaccines and global stability: achievements and challenges. Expert Rev Vaccine. 2008;7(10):1457-60.
2. Kristensen D, Chen D. Stabilization of vaccines: lessons learned. Hum Vaccine. 2010;6(3):229-31.
3. Brown DW, Burton A, Gacic-Dobo M, Karimov RI, Vandelaer J, Okwo-Bele JM. A mid-term assessment of progress towards the immunization coverage goal of the Global Immunization Vision and Strategy (GIVS). BMC Publ Health. 2011;11:806.
4. O'Brien J. Advancing vaccinology in India. Expert Rev Vaccine. 2011;11(1):27-9.
5. PATH. Immunization logistics and supply systems: From vision to action. Seattle: PATH; 2010.
6. Breen ED, Curley JG, Overcashier DE, Hsu CC, Shire SJ. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation. Pharm Res. 2001;18(9):1345-53. (Pubitemid 32846331)
7. Flores-Fernández GM, Pagán M, Almenas M, Solá RJ, Griebenow K. Moisture-induced solid state instabilities in alpha-chymotrypsin and their reduction through chemical glycosylation. BMC Biotechnol. 2010;10:57.
8. Flores-Fernández GM, Solá RJ, Griebenow K. The relation between moisture-induced aggregation and structural changes in lyophilized insulin. J Pharm Pharmacol. 2009;61(11):1555-61.
9. Jiang W, Schwendeman SP. Formaldehyde-mediated aggregation of protein antigens: comparison of untreated and formalinized model antigens. Biotechnol Bioeng. 2000;70(5):507-17.
10. Jain NK, Roy I. Accelerated stability studies for moisture-induced aggregation of tetanus toxoid. Pharm Res. 2011;28(3):626-39.
11. Aggerbeck H, Heron I. Detoxification of diphtheria and tetanus toxin with formaldehyde. Detection of protein conjugates. Biologicals. 1992;20(2):109-15.
12. Schwendeman SP, Costantino HR, Gupta RK, Siber GR, Klibanov AM, Langer R. Stabilization of tetanus and diphtheria toxoids against moisture-induced aggregation. Proc Natl Acad Sci USA. 1995;92(24):11234-8.
13. Quintilio W, Takata CS, Sant'Anna OA, da Costa MH, Raw I. Evaluation of a diphtheria and tetanus PLGA microencapsulated vaccine formulation without stabilizers. Curr Drug Deliv. 2009;6(3):297-304.
14. Determan AS, Wilson JH, Kipper MJ, Wannemuehler MJ, Narasimhan B. Protein stability in the presence of polymer degradation products: consequences for controlled release formulations. Biomaterials. 2006;27(17):3312-20. (Pubitemid 43344342)
15. Jiang W, Schwendeman SP. Stabilization of tetanus toxoid encapsulated in PLGA microspheres. Mol Pharm. 2008;5(5):808-17.
16. Hermann T, Patel DJ. Adaptive recognition by nucleic acid aptamers. Science. 2000;287(5454):820-5. (Pubitemid 30084318)
17. Fickert H, Fransson IG, Hahn U. Aptamers to small molecules. In: Klussmann S, editor. The aptamer handbook. Weinheim: Wiley VCH; 2006. p. 95-115.
18. Cerchia L, de Franciscis V. Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol. 2010;28(10):517-25.
19. Bunka DH, Platonova O, Stockley PG. Development of aptamer therapeutics. Curr Opin Pharmacol. 2010;10(5):557-62.
20. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov. 2010;9(7):537-50.
21. Schellekens H. Follow-on biologics: challenges of the "next generation". Nephrol Dial Transplant. 2005;20(S4):iv31-6. (Pubitemid 40711823)
22. Kresse GB. Biosimilars - science, status, and strategic perspective. Eur J Pharm Biopharm. 2009;72(3):479-86.
23. Fox A. Biosimilar medicines-new challenges for a new class of medicine. J Biopharm Stat. 2010;20(1):3-9.
24. Hermanson GT, Mallia KA, Smith PK. Immobilized affinity ligand techniques. New York: Academic; 1992. p. 53-6.
25. Uversky VN, Li J, Fink AL. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem. 2001;276(14):10737-44. (Pubitemid 38089246)
26. Sambrook J, Russell D. Molecular cloning: A laboratory manual. 3rd ed. New York: Cold Spring Harbor Laboratory Press; 2001. p. 1.31-8.
27. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54.
28. Jaganathan KS, Rao YU, Singh P, Prabakaran D, Gupta S, Jain A, et al. Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly(D, L-lactic-co-glycolic acid) versus chitosan microspheres. Int J Pharm. 2005;294(1-2):23-32. (Pubitemid 40462320)
29. Feng L, Qi XR, Zhou XJ, Maitani Y, Wang SC, Jiang Y, et al. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J Control Release. 2006;112(1):35-42.
30. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150(1):76-85. (Pubitemid 16258399)
31. Misra VK, Draper DE. The linkage between magnesium binding and RNA folding. J Mol Biol. 2002;317(4):507-21. (Pubitemid 34722166)
32. Nonaka Y, Sode K, Ikebukuro K. Screening and improvement of an anti-VEGF DNA aptamer. Molecules. 2010;15(1):215-20.
33. Lee J-H, Canny MD, De Erkenez A, Krilleke D, Ng Y-S, Shima DT, et al. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci USA. 2005;102(52):18902-7. (Pubitemid 43049539)
34. Di Tommaso P, Moretti S, Xenarios I, Orobitg M, Montanyola A, Chang JM, et al. T-Coffee: a web server for the multiple sequence alignment of protein and RNA sequences using structural information and homology extension. Nucleic Acids Res. 2011;39(Web server issue):W13-7.
35. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22(22):4673-80. (Pubitemid 24354800)
36. Edgar RC, Batzoglou S. Multiple sequence alignment. Curr Opin Struct Biol. 2006;16(3):368-73. (Pubitemid 43831644)
37. Chen CH, Chernis GA, Hoang VQ, Landgraf R. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc Natl Acad Sci USA. 2003;100(16):9226-31. (Pubitemid 37033911)
38. Soontornworajit B, Zhou J, Shaw MT, Fan TH, Wang Y. Hydrogel functionalization with DNA aptamers for sustained PDGF-BB release. Chem Commun (Camb). 2010;46(11):1857-9.
39. Soontornworajit B, Zhou J, Snipes MP, Battig MR, Wang Y. Affinity hydrogels for controlled protein release using nucleic acid aptamers and complementary oligonucleotides. Biomaterials. 2011;32(28):6839-49.
40. Carrasquillo KG, Ricker JA, Rigas IK, Miller JW, Gragoudas ES, Adamis AP. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co- glycolic)acid microspheres. Invest Ophthalmol Vis Sci. 2003;44(1):290-9. (Pubitemid 36134287)
41. Tan W, Wang H, Chen Y, Zhang X, Zhu H, Yang C, et al. Molecular aptamers for drug delivery. Trends Biotechnol. 2011;29(12):634-40.
42. Choi SI, Han KS, Kim CW, Ryu KS, Kim BH, Kim KH, et al. Protein solubility and folding enhancement by interaction with RNA. PLoS One. 2008;3(7):e2677.
43. Choi SI, Ryu K, Seong BL. RNA-mediated chaperone type for de novo protein folding. RNA Biol. 2009;6(1):21-4.
44. Choi SI, Lim KH, Seong BL. Chaperoning roles of macromolecules interacting with proteins in vivo. Int J Mol Sci. 2011;12(3):1979-90.
45. Costantino HR, Schwendeman SP, Griebenow K, Klibanov AM, Langer R. The secondary structure and aggregation of lyophilized tetanus toxoid. J Pharm Sci. 1996;85(12):1290-3. (Pubitemid 27014182)
46. Abbas SA, Sharma VK, Patapoff TW, Kalonia DS. Opposite effects of polyols on antibody aggregation: thermal versus mechanical stresses. Pharm Res. 2012;29(3):683-94.
47. Solanki VA, Jain NK, Roy I. Stabilization of tetanus toxoid formulation containing aluminium hydroxide adjuvant against freeze-thawing. Int J Pharm. 2011;414(1-2):140-7.
48. Solanki VA, Jain NK, Roy I. Stabilization of tetanus toxoid formulation containing aluminium hydroxide adjuvant against agitation. Int J Pharm. 2012;423(2):297-302.